Search results for " HIV Infections"

showing 8 items of 38 documents

Arginase activity in the blood of patients with visceral leishmaniasis and HIV infection.

2013

Background Visceral leishmaniasis is a parasitic disease associated with high mortality. The most important foci of visceral leishmaniasis in Ethiopia are in the Northwest and are predominantly associated with high rates of HIV co-infection. Co-infection of visceral leishmaniasis patients with HIV results in higher mortality, treatment failure and relapse. We have previously shown that arginase, an enzyme associated with immunosuppression, was increased in patients with visceral leishmaniasis and in HIV seropositive patients; further our results showed that high arginase activity is a marker of disease severity. Here, we tested the hypothesis that increased arginase activities associated wi…

MaleViral Diseasesmedicine.medical_treatmentEnzyme MetabolismHIV InfectionsParasite loadBiochemistrySeverity of Illness Index0302 clinical medicineBlood plasmaSUPPRESSOR-CELLSMACROPHAGESPLASMA AMINO-ACIDS0303 health sciencesCoinfectionPARASITOLOGYlcsh:Public aspects of medicineImmunosuppression11 Medical And Health SciencesIMMUNODEFICIENCY-VIRUS TYPE-13. Good healthEnzymesSEROPOSITIVE PATIENTSArginaseInfectious DiseasesCoinfectionMedicineLeishmaniasis VisceralBiological MarkersLife Sciences & BiomedicineResearch ArticleNeglected Tropical DiseasesAdultlcsh:Arctic medicine. Tropical medicineAdolescentlcsh:RC955-962030231 tropical medicineINHIBITIONPeripheral blood mononuclear cellMECHANISMS03 medical and health sciencesYoung AdultDONOVANITropical MedicinemedicineParasitic DiseasesACTIVATED GRANULOCYTESHumansAdolescent; Adult; Arginase/blood; Biological Markers/blood; Coinfection/diagnosis; Coinfection/pathology; Cross-Sectional Studies; Ethiopia; HIV Infections/complications; HIV Infections/diagnosis; Humans; Leishmaniasis Visceral/complications; Leishmaniasis Visceral/diagnosis; Male; Severity of Illness Index; Young AdultBiology030304 developmental biologyScience & TechnologyArginasebusiness.industryPublic Health Environmental and Occupational HealthLeishmaniasislcsh:RA1-127006 Biological Sciencesmedicine.diseaseVisceral leishmaniasisCross-Sectional StudiesImmunologyEthiopiabusinessBiomarkersRESPONSES
researchProduct

Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort

2019

Introduction: Concerns about dolutegravir (DTG) tolerability in the real-life setting have recently arisen. We aimed to estimate the risk of treatment discontinuation and virological failure of DTG-based regimens from a large cohort of HIV-infected individuals. Methods: We performed a multicentre, observational study including all antiretroviral therapy (ART)-naïve and virologically suppressed treatment-experienced (TE) patients from the Icona (Italian Cohort Naïve Antiretrovirals) cohort who started, for the first time, a DTG-based regimen from January 2015 to December 2017. We estimated the cumulative risk of DTG discontinuation regardless of the reason and for toxicity, and of virologica…

Maleadverse eventadverse events; antiretroviral therapy; cohort study; discontinuation; dolutegravir; toxicity; Adult; Anti-HIV Agents; Cohort Studies; Dideoxynucleosides; Female; HIV Infections; Heterocyclic Compounds 3-Ring; Humans; Italy; Male; Middle Aged; Prospective Studies; Retrospective Studies; Tenofovir; Treatment Outcomeadverse events; antiretroviral therapy; cohort study; discontinuation; dolutegravir; toxicity;HIV InfectionsPiperazinesCohort Studies0302 clinical medicineHeterocyclic CompoundsAbacavirRetrospective StudieMedicineHIV InfectionProspective Studies030212 general & internal medicineProspective cohort studyResearch Articlesadverse events; antiretroviral therapy; cohort study; discontinuation; dolutegravir; toxicityHazard ratioMiddle AgedDideoxynucleosidedolutegravirTreatment OutcomeInfectious DiseasesTolerabilityItalyCohortFemalePublic Health0305 other medical scienceHeterocyclic Compounds 3-RingResearch Articlemedicine.drugHumanAdultmedicine.medical_specialtyAnti-HIV AgentsPyridonesantiretroviral therapySettore MED/17 - MALATTIE INFETTIVE3-RingLower riskNO03 medical and health sciencesInternal medicineOxazinescohort studyHumansTenofovirRetrospective Studies030505 public healthbusiness.industryEnvironmental and Occupational HealthPublic Health Environmental and Occupational HealthAnti-HIV AgenttoxicityRetrospective cohort studyantiretroviral therapy; dolutegravir; cohort study; discontinuation; toxicity; adverse eventsDideoxynucleosidesadverse eventsDiscontinuationProspective Studieadverse events; antiretroviral therapy; cohort study; discontinuation; dolutegravir; toxicity; Public Health Environmental and Occupational Health; Infectious DiseasesCohort Studiebusinessdiscontinuation
researchProduct

Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients

2019

Maleantiretroviral treatmentInfectious Disease TransmissiongenotypeHuman immunodeficiency virus (HIV)Drug ResistanceHIV InfectionsDrug resistancemedicine.disease_causeRetrospective StudieGenotypepol Gene Products Human Immunodeficiency ViruPrevalenceMedicineVerticalHIV InfectionViralpol Gene ProductsYoung adultGeneral MedicineInfectious DiseasesItalyMutation (genetic algorithm)FemaleHuman Immunodeficiency VirusHumanMicrobiology (medical)AdultSettore MED/17 - Malattie InfettiveAdolescentAnti-HIV AgentsYoung AdultAcquired resistanceDrug Resistance ViralHumansvertical HIV transmissionAdolescent; Adult; Anti-HIV Agents; Drug Resistance Viral; Female; HIV Infections; HIV-1; Humans; Italy; Male; Mutation; Prevalence; Retrospective Studies; Young Adult; pol Gene Products Human Immunodeficiency Virus; Infectious Disease Transmission VerticalRetrospective StudiesHIV perinatally infectionbusiness.industryAnti-HIV AgentRetrospective cohort studyVirologyInfectious Disease Transmission VerticalLarge cohortpol Gene Products Human Immunodeficiency VirusDrug resistanceMutationHIV-1Drug resistance; HIV-1; antiretroviral treatment; genotype; vertical HIV transmissionbusiness
researchProduct

Role of HLA-B α-3 domain amino acid position 194 in HIV disease progression

2013

HLA class I molecules play a role in the regulation of innate immune response. Therefore, the interaction of HLA class I molecules with different activating and inhibitory receptors leads to balancing the immune response. Among the different family of receptors, NK receptors KIR3DL1/S1 and LIR1, play a major role. Aim of this study was to evaluate the role of amino acid polymorphic positions of HLA class I molecules interacting with NK receptors in HIV progression. In order to minimize the influence of viral variability, a cohort of children with a nosocomial monophyletic HIV-1 infection from the Benghazi Children Hospital has been evaluated. To assess the role of single amino acid position…

Models MolecularGene ExpressionKIR3DS1HIV InfectionsPeptide bindingLeukocyte Immunoglobulin-like Receptor B1ModelsImmunologicReceptorsInnateReceptors ImmunologicChildReceptorGeneticschemistry.chemical_classificationCross Infectioneducation.field_of_studyReceptors KIR3DL1Polymorphism Genetic; Models Molecular; Humans; Disease Progression; Gene Expression; HLA-B Antigens; Immunity Innate; Child; Receptors KIR3DL1; Protein Binding; HIV-1; Binding Sites; Receptors KIR3DS1; Receptors Immunologic; HIV Infections; Antigens CD; Protein Structure Tertiary; Signal Transduction; Amino Acid Substitution; Cross InfectionHLA-BCDAmino acidDisease ProgressionKIR3DL1Protein BindingSignal TransductionReceptors KIR3DS1Protein StructureImmunologyPopulationHuman leukocyte antigenBiologyGeneticKIR3DL1Antigens CDHumansPolymorphismAntigenseducationMolecular BiologySettore MED/04 - Patologia GeneralePolymorphism GeneticBinding SitesInnate immune systemImmunityMolecularImmunity InnateProtein Structure TertiaryAmino Acid SubstitutionchemistryHLA-B AntigensImmunologyHIV-1TertiaryMolecular Immunology
researchProduct

A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen

2011

Abstract Background HIV-1 genotypic susceptibility scores (GSSs) were proven to be significant prognostic factors of fixed time-point virologic outcomes after combination antiretroviral therapy (cART) switch/initiation. However, their relative-hazard for the time to virologic failure has not been thoroughly investigated, and an expert system that is able to predict how long a new cART regimen will remain effective has never been designed. Methods We analyzed patients of the Italian ARCA cohort starting a new cART from 1999 onwards either after virologic failure or as treatment-naïve. The time to virologic failure was the endpoint, from the 90th day after treatment start, defined as the firs…

OncologyMaleAdult; Anti-HIV Agents; Cohort Studies; Drug Therapy Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Proportional Hazards Models; Treatment Failure; Viral LoadHIV InfectionsCohort Studies0302 clinical medicineANTIRETROVIRAL THERAPYMedicineHIV Infection030212 general & internal medicineTreatment Failure0303 health sciencesHealth PolicyMiddle AgedViral Load3. Good healthComputer Science ApplicationsCensoring (clinical trials)CohortCombinationlcsh:R858-859.7Drug Therapy CombinationFemaleViral loadHumanResearch ArticleCartAdultmedicine.medical_specialtyAnti-HIV AgentsHIV-1; antiretroviral therapyHealth InformaticsSettore MED/17 - MALATTIE INFETTIVElcsh:Computer applications to medicine. Medical informatics03 medical and health sciencesDrug TherapyInternal medicineHumansSurvival analysisProportional Hazards Models030306 microbiologybusiness.industryProportional hazards modelAdult; Anti-HIV Agents; Cohort Studies; Drug Therapy Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Proportional Hazards Models; Treatment Failure; Viral Load; Health Informatics; Health PolicyANTIRETROVIRAL DRUGSAnti-HIV AgentHIVGENOTYPESDiscontinuationRegimenImmunologyProportional Hazards ModelHIV-1Cohort StudiebusinessBMC Medical Informatics and Decision Making
researchProduct

An adaptive multimeme algorithm for designing HIV multidrug therapies.

2007

This paper proposes a period representation for modeling the multidrug HIV therapies and an Adaptive Multimeme Algorithm (AMmA) for designing the optimal therapy. The period representation offers benefits in terms of flexibility and reduction in dimensionality compared to the binary representation. The AMmA is a memetic algorithm which employs a list of three local searchers adaptively activated by an evolutionary framework. These local searchers, having different features according to the exploration logic and the pivot rule, have the role of exploring the decision space from different and complementary perspectives and, thus, assisting the standard evolutionary operators in the optimizati…

ScheduleMathematical optimizationComputer scienceAnti-HIV AgentsHIV therapy designAdaptive algorithms; HIV therapy design; Memetic algorithms; Nonlinear integer programming; Algorithms; Anti-HIV Agents; Biomimetics; Computer Simulation; Drug Combinations; Drug Design; Drug Therapy Computer-Assisted; HIV Infections; Humans; Immunity Innate; Models ImmunologicalHIV InfectionsReduction (complexity)Computer-AssistedDrug TherapyModelsBiomimeticsGeneticsInnateHumansComputer SimulationRepresentation (mathematics)MetaheuristicStatistical hypothesis testingFlexibility (engineering)Applied MathematicsNonlinear integer programmingImmunityModels ImmunologicalAdaptive algorithmsImmunity InnateDrug Therapy Computer-AssistedDrug CombinationsImmunologicalDrug DesignMemetic algorithmsMemetic algorithmAlgorithmAlgorithmsBiotechnologyPremature convergenceIEEE/ACM transactions on computational biology and bioinformatics
researchProduct

Vitamin D Deficiency in HIV Infection: Not Only a Bone Disorder

2015

Hypovitaminosis D is a worldwide disorder, with a high prevalence in the general population of both Western and developing countries. In HIV patients, several studies have linked vitamin D status with bone disease, neurocognitive impairment, depression, cardiovascular disease, high blood pressure, metabolic syndrome, type 2 diabetes mellitus, infections, autoimmune diseases like type 1 diabetes mellitus, and cancer. In this review, we focus on the most recent epidemiological and experimental data dealing with the relationship between vitamin D deficiency and HIV infection. We analysed the extent of the problem, pathogenic mechanisms, clinical implications, and potential benefits of vitamin …

Settore MED/09 - Medicina InternaBone diseasePopulationlcsh:MedicineHIV InfectionsReview ArticleDiseaseGeneral Biochemistry Genetics and Molecular Biologyvitamin D deficiencyRisk FactorsAntiretroviral Therapy Highly ActivePrevalenceVitamin D and neurologyHumansMedicineHIV InfectionAntiretroviral Therapy Highly Active; HIV Infections; Humans; Prevalence; Risk Factors; Vitamin D Deficiency; Bone Diseases; Biochemistry Genetics and Molecular Biology (all); Immunology and Microbiology (all)educationeducation.field_of_studyType 1 diabetesGeneral Immunology and Microbiologybusiness.industryRisk Factorlcsh:RType 2 Diabetes MellitusVitamin D Deficiency; HIV Infection; Bone DisorderGeneral MedicineVitamin D Deficiencymedicine.diseaseImmunologyBone DiseasesMetabolic syndromebusinessHumanBioMed Research International
researchProduct

Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study

2021

This study evaluates the frequency and causes of dolutegravir (DTG) discontinuation along 5 years of follow-up, in both antiretroviral treatment (ART)-naive and experienced people living with HIV (PLWH). This is a prospective multi-center cohort study enrolling PLWH on DTG from July 2014 until November 2020. DTG-durability was investigated using the Kaplan-Meier survival curve. The Cox proportional-hazards model was used for estimating the hazard ratio (HR) of DTG discontinuation for any cause, and for adverse events (AEs). Nine hundred sixty-three PLWH were included, 25.3% were women and 28.0% were ART-naive. Discontinuations for any causes were 10.1 [95% confidence interval (95% CI) 8.9-1…

adverse events; dolutegravir; durability; HIV; safety; toxicity; virolgical failure; Cohort Studies; Female; Heterocyclic Compounds 3-Ring; Humans; Middle Aged; Oxazines; Piperazines; Prospective Studies; Pyridones; Anti-HIV Agents; HIV InfectionssafetyPediatricsmedicine.medical_specialtySettore MED/17 - Malattie InfettivePyridonesAnti-HIV AgentsOxazineHuman immunodeficiency virus (HIV)adverse eventHIV Infectionsvirolgical failurePyridonemedicine.disease_cause3-RingHIV Infections.PiperazinesCohort Studieschemistry.chemical_compoundHeterocyclic CompoundsHIV; adverse events; dolutegravir; durability; safety; toxicity; virolgical failureOxazinesAntiretroviral treatmentMedicineHumansProspective StudiesAdverse effectPiperazinebusiness.industryPublic Health Environmental and Occupational HealthHIVtoxicityAnti-HIV AgentMiddle Agedadverse eventsDiscontinuationdolutegravirvirolgical failure.Prospective StudieInfectious DiseaseschemistryDolutegravirdurabilityObservational studyFemaleCohort StudiebusinessHeterocyclic Compounds 3-RingHuman
researchProduct